LYTIR

Company · BRVE

Braveheart Bio, Inc.

Nasdaq's symbol directory lists BRVE on Nasdaq as “Braveheart Bio, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 9 occasions ($124.1M); 5 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Forbion Growth Opportunities Fund III Cooperatief U.A. bought on 1 day latest Aug 7, 2026 bought $64.8M
  2. ORBIMED ADVISORS LLC bought on 1 day latest Aug 7, 2026 bought $34.9M
  3. AH Bio Fund IV, L.P. bought on 1 day latest Aug 7, 2026 bought $19.8M
  4. Viehbacher Christopher bought on 1 day latest Aug 7, 2026 bought $1.5M
  5. Murdoch Travis, CEO and President bought on 1 day latest Aug 7, 2026 bought $1.5M
  6. Lubner David Charles bought on 1 day latest Aug 7, 2026 bought $1.0M
  7. James Paul Rickey, Chief Financial Officer bought on 1 day latest Aug 7, 2026 bought $500K
  8. Malek David I bought on 1 day latest Aug 7, 2026 bought $75K
  9. Anderson Michele A., Chief Development Officer bought on 1 day latest Aug 7, 2026 bought $20K
Every trade (9)
  1. BUYForbion Growth Opportunities Fund III Cooperatief U.A. bought Aug 7, 2026 3,600,000 shares 2 legs combined filing $64.8M
  2. BUYORBIMED ADVISORS LLC bought Aug 7, 2026 1,940,000 shares 2 legs combined filing $34.9M
  3. BUYAH Bio Fund IV, L.P. bought Aug 7, 2026 1,100,000 shares filing $19.8M
  4. BUYViehbacher Christopher bought Aug 7, 2026 83,333 shares filing $1.5M
  5. BUYMurdoch Travis, CEO and President bought Aug 7, 2026 83,333 shares filing $1.5M
  6. BUYLubner David Charles bought Aug 7, 2026 55,555 shares filing $1.0M
  7. BUYJames Paul Rickey, Chief Financial Officer bought Aug 7, 2026 27,777 shares filing $500K
  8. BUYMalek David I bought Aug 7, 2026 4,166 shares filing $75K
  9. BUYAnderson Michele A., Chief Development Officer bought Aug 7, 2026 1,111 shares filing $20K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. FMR LLC filed Nov 5, 2026 Schedule 13G passive 7,374,365 shares filing 8.2%
  2. ORBIMED ADVISORS LLC filed Sep 10, 2026 Schedule 13D/A may seek influence 12,175,159 shares filing 13.5%
  3. ORBIMED ADVISORS LLC filed Aug 18, 2026 Schedule 13D may seek influence 12,175,159 shares filing 17.2%
  4. AH Bio Fund IV, L.P. filed Aug 14, 2026 Schedule 13D may seek influence 10,232,420 shares filing 11.4%
  5. Frazier Life Sciences Public Fund, L.P. filed Aug 14, 2026 Schedule 13G passive filing 5.5%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Regulation FD disclosure filing Nov 6, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.